

## Synthesis of 3,1-Benzoxazines, 3,1-Benzothiazines and 3,1-Benzoxazepines via N-Arylimino-1,2,3-dithiazoles

Thierry Besson,<sup>a\*</sup> Gérald Guillaumet,<sup>b</sup> Christelle Lamazzi<sup>a,b</sup> and Charles W. Rees<sup>c</sup>

<sup>a</sup> Laboratoire de Génie Protéique et Cellulaire, Groupe de Chimie Organique, Pôle Sciences et Technologie, Université de La Rochelle, Avenue Marillac, F-17042 La Rochelle cedex 1, FRANCE. Fax (33) 05 46 45 82 47; e-mail : tbesson@bio.univ-lr.fr


<sup>b</sup> Institut de Chimie Organique et Analytique, associé au CNRS, Université d'Orléans, BP 6759, rue de Chartres, F-45067 Orléans cedex 2, FRANCE

<sup>c</sup> Department of Chemistry, Imperial College of Science, Technology and Medicine, London SW7 2AY, UK

Received 18 March 1997

**Abstract :** *o*-Aminobenzyl alcohols are converted in two steps into 3,1-benzoxazines **7** and 3,1-benzothiazines **8**, and *o*-aminophenethyl alcohol is converted into 3,1-benzoxazepine **9**.

We have shown that 4,5-dichloro-1,2,3-dithiazolium chloride **1**, which is readily prepared from chloroacetonitrile and disulfur dichloride, reacts rapidly with anilines in the presence of pyridine to give very stable, pale yellow to orange, *N*-arylimines **2**.<sup>1</sup> We have studied the effect of varying substituents in the aniline ring.<sup>1-3</sup> Thus, neighbouring groups such as carboxylic acid and nitrile introduced into the *ortho* position of the *N*-aryl group of the imines **2** allowed formation of novel 3,1-benzoxazin-4-ones **3**,<sup>3</sup> 3,1-benzothiazin-4-ones **4**<sup>3</sup> and 4-alkoxyquinazolines **5**,<sup>4</sup> derivatives of which continue to be of interest because of their diverse biological activity [e.g. potent alternate inhibitors of human leucocyte elastase, herpes simplex (HSV-1) and C1 complex (Clr) serine proteases and porcine cyclic GMP phosphodiesterase].<sup>5</sup>




In this paper we report that introduction of a hydromethyl group into the *ortho* position of the iminodithiazole **2** allows access to the benzoxazine and benzothiazine rings (products **7** and **8**) in moderate to good yields. The dihydro-3,1-benzoxazepine **9** was also prepared in two steps from *o*-aminophenethyl alcohol.

Primary aromatic amines **6**<sup>6,7</sup> were condensed with 4,5-dichloro-1,2,3-dithiazolium chloride **1** in dichloromethane at room temperature, followed by addition of pyridine, to give the iminodithiazoles **2a-d** in good yield (Scheme 1).<sup>8</sup>

Amine	n	R	Product	yield (%)	mp(C°)
<b>6 a</b>	1	H	<b>2 a</b>	60	142
<b>6 b</b>	1	4-Me	<b>2 b</b>	70	116
<b>6 c</b>	1	5-Cl	<b>2 c</b>	75	145
<b>6 d</b>	2	H	<b>2 d</b>	71	oil


Scheme 1

A mixture of 2-cyanobenzoxazines **7** and 2-cyanobenzothiazines **8** (approximate ratio 8:1) was obtained by heating the starting imines **2a-c** in THF at reflux in the presence of 2 equiv. of sodium hydride for approximately 1 h (Scheme 2). Direct separation and purification of the two products was difficult and needed three recrystallizations. Treatment of the reaction mixture with an excess of *m*-chloroperbenzoic acid allowed an easier isolation of the benzoxazines **7** from the S-oxides of **8** by column chromatography (Table, method A).



Scheme 2


Mechanisms for the formation of **7** and **8** are proposed in Scheme 3. The oxygen-containing rings **7** and **9** are probably formed by cyclisation of the alkoxide from **2** onto the imine bond, followed by loss of singlet diatomic sulfur to generate the cyano group. The formation of the sulfur compounds **8** may involve opening of the dithiazole ring (see below) by hydride,<sup>9</sup> followed by elimination of H<sub>2</sub>S and H<sub>2</sub>O, as shown, to give the reactive intermediate **10** which cyclises to the stable product.



Scheme 3

The benzothiazine ring may also be obtained, in much better yield, by heating the imino-1,2,3-dithiazoles **2a-c** in dichloromethane at reflux in the presence of 2 equiv. of triphenylphosphine (Table, method B). As we

previously suggested for the synthesis of 2-cyano-3,1-benzothiazin-4-ones **4**,<sup>3</sup> initial attack by phosphorus on S-2 of the 1,2,3-dithiazole **2** will open the dithiazole ring with formation of the intermediate disulfide **11**. Attack by a second triphenylphosphine on the same sulfur results in elimination of  $\text{Ph}_3\text{P=S}$  and  $\text{Ph}_3\text{P=O}$  to give the reactive intermediate **10** which cyclises to the stable benzothiazine **8** in good yield (Scheme 4).



Scheme 4

**Table.** Synthesis of benzoxazines **7**, benzothiazines **8** and benzoxazepine **9** from imines **2**.<sup>10</sup>

Starting imines	Method <sup>a</sup>	Product	Yield of product <sup>b</sup> (%)
<b>2a</b>	A	<b>7a</b>	44 (55 : 5)
<b>2a</b>	B	<b>8a</b>	58
<b>2b</b>	A	<b>7b</b>	54 (60 : 10)
<b>2b</b>	B	<b>8b</b>	65
<b>2c</b>	A	<b>7c</b>	30 (44 : 6)
<b>2c</b>	B	<b>8c</b>	80
<b>2d</b>	A	<b>9</b>	50

<sup>a</sup> Method A : NaH (2 equiv.), THF reflux; method B : PPh<sub>3</sub> (2 equiv.), CH<sub>2</sub>Cl<sub>2</sub> reflux. <sup>b</sup> In brackets : yields of compounds (**7** : **8**) after a rapid separation by column chromatography and before treatment of the mixture by MCPBA (determined by <sup>1</sup>H-NMR spectroscopy).

In conclusion, these reactions provide a simple route to benzo fused derivatives of 2-cyanooxazines and 2-cyanothiazines. Functional groups at the 2-position of these ring systems are not common and 2-cyano groups are very rare. To our knowledge 2-cyano-3,1-benzoxazepines have not been reported before.

**Acknowledgements.** We thank the society ADIR (Groupe Servier) and the Comité de Charente-Maritime de la Ligue Nationale Contre le Cancer for financial support. We are also grateful to the Wolfson Foundation for establishing the Wolfson Centre for Organic Chemistry in Medical Science at Imperial College.

## References and notes

- (1) Rees, C. W. *J. Heterocycl. Chem.* **1992**, *29*, 639.
  - (2) Besson, T.; Rees, C. W. *J. Chem. Soc., Perkin Trans. I* **1995**, 1659.
  - (3) (a) Besson, T.; Emayan, K.; Rees, C. W. *J. Chem. Soc., Perkin Trans. I* **1995**, 2097; (b) Besson, T.; Emayan, K.; Rees, C. W. *J. Chem. Soc., Chem. Commun.* **1995**, 1419.
  - (4) Besson, T.; Rees, C. W. *J. Chem. Soc., Perkin Trans. I* **1996**, 2857.
  - (5) (a) Krantz, A.; Spencer, R. W.; Tam, T. F.; Liak, T. J.; Copp, L. J.; Thomas, E. M.; Rafferty, S. P. *J. Med. Chem.* **1990**, *29*, 1349. (b) Jarvest, L. R.; Parratt, M. J.; Debouck, C. M.; Gorniak, J. G.; Jennings, L. J.; Serafinowska, H. T.; Strickler, J. E. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 2463 (c) Gilmore, J. L.; Hays, S. J.; Caprathe, B. W.; Lee, C.; Emmerling, M. R.; Michael, W.; Jaen, J. C. *Bioorg. Med. Chem. Lett.* **1996**, *6*, 679. (d) Takase, Y.; Saeki, T.; Watanabe, N.; Adachi, H.; Souda, S.; Saito, I. *J. Med. Chem.* **1994**, *37*, 2106.
  - (6) Starting amines are commercially available excepted for the 5-chloro derivative **6c** which was synthesized by reduction of 2-amino-4-chlorobenzoic acid by the procedure described in ref. 7.
  - (7) Nystrom, R. F.; Brown, W. G. *J. Am. Chem. Soc.* **1947**, *69*, 2548.
  - (8) Appel, R.; Janssen, H.; Siray, M.; Knoch, F. *Chem. Ber.* **1985**, *118*, 1632.
  - (9) A similar mechanism was suggested for reduction by HCl/NaBH<sub>3</sub>CN; Lee H.; Kim, K. *Heteroatom. Chem.* **1993**, *4*, 263.
  - (10) All compounds were fully characterized by spectroscopy and elemental analysis; selected data for new compounds **2a**, **2b** and **2d**; **7a**, **8a**, **8c** and **9**.
- 4-Chloro-5-(2-hydroxymethylphenylimino)-5H-1,2,3-dithiazole 2a:** orange needles, mp 142°C, IR (KBr), v 3200 (OH), 2926, 2863, 1698, 1600, 1568, 1480, 1450, 1364, 1224, 1186, 1144, 1033 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>+D<sub>2</sub>O): δ 4.74 (s, 2H, CH<sub>2</sub>OH), 7.25-7.45 (m, 4H, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ 63.40, 115.76, 127.36, 128.83, 129.11, 135.01, 147.41, 148.46, 153.43; MS (EI) m/z 258 (M<sup>+</sup>, 22%), 194 (M<sup>+</sup>-S<sub>2</sub>, 25), 159 (M<sup>+</sup>-[S<sub>2</sub>Cl], 55), 132 (M<sup>+</sup>-[S<sub>2</sub>-N=C-Cl], 100). HRMS: calcd. for C<sub>9</sub>H<sub>7</sub>ClN<sub>2</sub>OS<sub>2</sub>: 257.9688, found 257.9680.
- 4-Chloro-5-(4-methyl-2-hydroxymethylphenylimino)-5H-1,2,3-dithiazole 2b:** yellow needles, mp 144°C, IR (KBr), v 3253 (OH), 2936, 1610, 1591, 1481, 1230, 1141, 1109, 1046, 1017 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>+D<sub>2</sub>O): δ 2.38 (s, 3H, CH<sub>3</sub>), 4.72 (s, 2H, CH<sub>2</sub>OH), 7.18-7.34 (m, 3H, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ = 21.71, 63.98, 116.08, 129.42, 130.30, 135.86, 138.09, 144.76, 149.10, 156.25; MS (EI) m/z = 272 (M<sup>+</sup>, 23%), 208 (M<sup>+</sup>-S<sub>2</sub>, 14), 173 (M<sup>+</sup>-[S<sub>2</sub>Cl], 49), 146 (M<sup>+</sup>-[S<sub>2</sub>-N=C-Cl], 100). HRMS: calcd. for C<sub>10</sub>H<sub>9</sub>ClN<sub>2</sub>OS<sub>2</sub>: 271.9844, found 271.9838.
- 4-Chloro-5-(5-chloro-2-hydroxymethylphenylimino)-5H-1,2,3-dithiazole 2c:** yellow needles, mp 116°C, IR (KBr), v 3289 (OH), 2905, 1602, 1557, 1537, 1505, 1478, 1393, 1220, 1143, 1036 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>+D<sub>2</sub>O): δ = 4.75 (s, 2H, CH<sub>2</sub>OH), 7.307 (dd, 1H, J = 2.1 and 8.3 Hz, Harom), 7.38 (d, 1H, J = 2.1 Hz, Harom), 7.46 (d, 1H, J = 8.3 Hz, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ = 62.89, 116.55, 127.31, 130.61, 133.50, 134.76, 148.68, 149.09, 159.35; MS (EI) m/z 292 (M<sup>+</sup>, 24%), 228 (M<sup>+</sup>-S<sub>2</sub>, 34), 193 (M<sup>+</sup>-[S<sub>2</sub>Cl], 51), 166 (M<sup>+</sup>-[S<sub>2</sub>-N=C-Cl], 100). HRMS: calcd. for C<sub>9</sub>H<sub>6</sub>Cl<sub>2</sub>N<sub>2</sub>OS<sub>2</sub>: 291.9298, found 291.9300.
- 4-Chloro-5-[2-(2-hydroxyethyl)phenylimino]-5H-1,2,3-dithiazole 2d:** orange oil; IR (neat), v 3381, 2927, 1588, 1570, 1481, 1447, 1264, 1223, 1146, 1043 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>+D<sub>2</sub>O): δ 2.95 (t, 2H, J = 6.28 Hz, CH<sub>2</sub>CH<sub>2</sub>OH), 3.85 (t, 2H, J = 6.28 Hz, CH<sub>2</sub>CH<sub>2</sub>OH), 7.15-7.35 (m, 4H, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ 35.82, 63.83, 116.27, 127.55, 128.49, 131.74, 132.93, 148.49, 149.82, 158.53.
- 4H-3,1-Benzoxazine-2-carbonitrile 7a:** colourless needles, mp 89°C; IR (KBr), v 2888, 2244 (CN), 1626, 1601, 1487, 1463, 1250, 1183, 1006 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>): δ 5.40 (s, 2H, CH<sub>2</sub>O), 6.97 (dd, 1H, J = 1.8 and J = 8.6 Hz, Harom), 7.23 (dd, 1H, J = 1.8 and J = 8.6 Hz, Harom), 7.30 (m, 2H, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>): δ = 67.96, 112.01, 122.26, 124.65, 126.44,

130.10, 130.32, 136.44, 136.9; MS (EI) m/z 158 ( $M^+$ , 100%), 132 ( $M^+-CN$ , 20), 103 ( $M^+-1-[O-C-CN]$ , 58). HRMS: calcd. for  $C_9H_6N_2O$ : 158.0480, found 158.0487.

**6-Methyl-4H-3,1-benzoxazine-2-carbonitrile 7b:** white needles, mp 124°C (Lit.<sup>9</sup> : 121-123°C).

**7-Chloro-4H-3,1-benzoxazine-2-carbonitrile 7c:** pale yellow needles, mp 94°C; IR (KBr), v 2923, 2244 (CN), 1627, 1593, 1458, 1376, 1249, 1178, 1122, 1078 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  5.39 (s, 2H, CH<sub>2</sub>O), 6.93 (d, 1H, J = 8 Hz, Harom), 7.27 (dd, 1H, J = 2.4 and J = 8 Hz, Harom), 7.30 (d, 1H, J = 2.4 Hz, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>):  $\delta$  67.24, 111.24, 120.02, 125.22, 126.13, 129.65, 135.23, 136.81, 137.62; MS (EI) m/z 192 ( $M^+$ , 55%), 166 ( $M^+-CN$ , 17), 157 ( $M^+-Cl$ , 45). HRMS: calcd. for  $C_9H_5ClN_2O$ : 192.0090, found 192.0090.

**4H-3,1-Benzothiazine-2-carbonitrile 8a:** colourless needles, mp 86°C; IR (KBr), v 2923, 2232 (CN), 1574, 1525, 1455, 1306, 1159, 1111, 1075 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  4.05 (s, 2H, CH<sub>2</sub>S), 7.14 (m, 1H, Harom), 7.40 (m, 3H, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>):  $\delta$  27.98, 114.04, 117.78, 127.48, 128.14, 129.39, 131.12, 135.33, 142.34; MS (EI) m/z 174 ( $M^+$ , 100%), 148 ( $M^+-CN$ , 3). HRMS: calcd. for  $C_9H_6N_2S$ : 174.0251, found 174.0260.

**6-Methyl-4H-3,1-benzothiazine-2-carbonitrile 8b:** white needles, mp 102°C (Lit.<sup>9</sup> : 105°C).

**7-Chloro-4H-3,1-benzothiazine-2-carbonitrile 8c:** pale yellow needles, mp 149°C; IR (KBr), v 2971, 2235 (CN), 1562, 1530, 1470, 1421, 1124, 1077 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  4.03 (s, 2H, CH<sub>2</sub>S), 7.09 (d, 1H, J = 8.3 Hz, Harom), 7.37 (dd, 1H, J = 2 and J = 8.3 Hz, Harom), 7.40 (d, 1H, J = 2 Hz, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>):  $\delta$  27.62, 113.74, 116.15, 127.96, 128.45, 130.77, 134.94, 137.12, 143.11; MS (EI) m/z 208 ( $M^+$ , 61%), 182 ( $M^+-CN$ , 3), 173 ( $M^+-Cl$ , 100). HRMS: calcd. for  $C_9H_5ClN_2S$ : 207.9862, found 207.9873.

**3,1-Benzazepine-2-carbonitrile 9:** white needles, mp 80°C; IR (KBr), v 2923, 2243 (CN), 1660, 1597, 1484, 1455, 1266, 1225, 1180 cm<sup>-1</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  3.19 (t, 2H, J = 4.4 Hz, CH<sub>2</sub>), 4.53 (t, 2H, J = 4.4 Hz, CH<sub>2</sub>O), 7.12 (dd, 1H, J = 1.5 and J = 8 Hz, Harom), 7.20 (dt, 1H, J = 1.5 and J = 8 Hz, Harom), 7.28 (dt, 1H, J = 1.5 and J = 8 Hz, Harom), 7.39 (dd, 1H, J = 1.5 and J = 8 Hz, Harom); <sup>13</sup>C-NMR (CDCl<sub>3</sub>):  $\delta$  36.84, 53.50, 73.05, 113.22, 128.01, 128.98, 129.98, 130.74, 135.93, 140.97; MS (EI) m/z 172 ( $M^+$ , 100%), 142 ( $M^+-CH_2O$ , 85), 118 ( $M^+-[O-C-CN]$ , 78). HRMS: calcd. for  $C_{10}H_8N_2O$ : 172.0636, found 172.0630.